Include related FDA-required labeling data for context when presenting related new information

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

FDA recommends that when the FDA-required labeling contains data or information related to what a CFL promotional communication (labeling, or prescription drug / restricted device advertising, that is consistent with the FDA-required labeling) represents or suggests, the communication also include the labeling's data or information, presented clearly and prominently, for context.

Check

Where new (e.g., postmarketing) data is presented on a topic the label already addresses (e.g., adverse event rates), check whether the corresponding labeling data is also included clearly and prominently. A violation looks like new data presented with no comparison to the labeled data on the same topic.

Escalate when

It is unclear whether the labeling data is sufficiently 'related' to the new information to require inclusion.

Where this comes from

Q.8/A.8, bullet 3 · page 18. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…uated the effect of the product on two different endpoints, such as overall survival and progression-free survival, and the product failed to demonstrate an effect on one of these two endpoints, the firm should clearly and prominently disclose this in the CFL Contains Nonbinding Recommendations promotional communication, rather than selectively presenting only the positive efficacy results. If the FDA-required labeling contains data or information related to what is being represented/suggested in the CFL promotional communication, the communication should also include the data or information from the FDA-required labeling to provide the audience with appropriate context, and this information should be presented in a clear and prominent way. For example, if a communication provides postmarketing information about the types and rates of occurrence of adverse events that have been observed in practice, the communication should also include information from the FDA-required labeling about the types and rates of occurrence of adverse reactions observed in clinical trials to provide context. These considerations are not intended to be a comprehensive descri…

Open the original at page 18 on fda.gov ↗Read our full copy →

Document: FDA guidance: Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: 1a18b7f242bfbbf897f198df…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

Basisconsistent-with-labeling

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- Squarely supported by A.8 bullet 3, quoted verbatim, and the Check tracks the example FDA gives in that same bullet: where a communication provides postmarketing information about types and rates of adverse events observed in practice, it 'should also include information from the FDA-required labeling about the types and rates of occurrence of adverse reactions observed in clinical trials to provide context.' The non-binding framing ('FDA recommends') is preserved.
- Scope is broader than the source. The rule statement says 'a communication' and applies_when carries no basis limiter, while the source's recommendation is about a 'CFL promotional communication' and is expressly 'applicable only to drug and device labeling and prescription drug and restricted device advertising that are consistent with the FDA-required labeling.'
- One requirement (include the related FDA-required labeling data, clearly and prominently), so atomic. 'Judgment' is correct: whether labeling data is sufficiently 'related,' and whether the inclusion is clear and prominent, are interpretive. 'Guidance' is correct and the locator (bullet 3) is right. 'Warning' is defensible, though it sits oddly below the 'blocker' assigned to US-FB-008 for the closely related omission of unfavorable findings — worth a consistency pass on severities across this category.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is the complete third bullet of Q.8/A.8. It says the communication 'should also include' related data or information from the FDA-required labeling for context, and that this 'should be presented in a clear and prominent way'. The rule text says 'FDA recommends', so it does not turn guidance into an obligation. The title is imperative but does not say 'must'.
- 'Presented clearly and prominently' describes how the single recommended inclusion is made. It is not a separate requirement, so the rule is atomic.
- Whether the labeling data is 'related' and whether it is presented clearly and prominently are matters of judgment, so 'judgment' is correct. applies_when (promotional; consistent-with-labeling) matches the guidance's CFL promotional communication scope. The rule text also correctly limits that scope to labeling and to Rx drug / restricted device advertising, which the vocabulary cannot express. Warning severity and the locator are correct. The Check's example (postmarketing AE rates alongside labeled trial rates) mirrors the source's own example.